Delhi High Court rejects Novo Nordisk's plea for interim injunction against Dr Reddy's Labs over semaglutide. Court cites 'evergreening', allows DRL to export. Key ruling for diabetes drug market.
A recent Delhi High Court order in the Novo Nordisk vs Dr Reddy's case highlights the complexities of Indian patent litigation. We examine the system's challenges and the push for specialized IP courts.
HSBC sees Dr Reddy's Canada semaglutide opportunity intact. Goldman Sachs bullish on Titan's 15-20% jewellery growth. CLSA positive on Power Grid's battery storage entry. Get the full analysis.
Delhi High Court permits Dr Reddy's to export generic semaglutide, a major win for Indian drugmakers eyeing the booming anti-obesity market. Read the full analysis.
Eli Lilly reduces Zepbound's starting price to $299 monthly, intensifying its price war with Novo Nordisk's Ozempic and Wegovy. New discounts aim to expand access to blockbuster weight-loss drugs.
Novo Nordisk and Eli Lilly develop daily oral weight loss pills with 10-16% average weight loss in trials. Pending FDA approval, these could replace injections.
Novo Nordisk reduces Wegovy's price to $349 and prepares an aggressive launch for its oral weight-loss pill to combat competition from Eli Lilly and expand patient access.
Lars Rebien Sorensen returns as Novo Nordisk chairman after board shakeup. The move follows Pfizer's $10B Metsera acquisition, intensifying obesity drug competition.
European weight-loss drug makers surge as investors rotate capital from expensive AI stocks into healthcare. Zealand Pharma leads with a 20% weekly jump. Explore the market dynamics.
Novo Nordisk reduces Wegovy price by 37% in India, intensifying the weight loss drug war with Eli Lilly's Mounjaro. Discover the new costs and market impact.
Novo Nordisk reduces its weight loss drug Wegovy's price by 37% in India, intensifying competition with Eli Lilly's Mounjaro. Get the latest details on the new pricing and market dynamics.
Novo Nordisk reduces Wegovy's price by 37% in India as it faces patent loss and competition from Eli Lilly's Mounjaro and upcoming generic versions. Discover the new costs.
Trump administration secures obesity drug price cuts with Eli Lilly and Novo Nordisk. Medicare coverage expansion opens 30 million patient market starting April 2026. Read analysis.
Former President Donald Trump reveals groundbreaking agreement with pharmaceutical giants to dramatically reduce costs of popular weight loss medications, promising relief for millions struggling with obesity.
In a major victory for American patients, pharmaceutical titans Eli Lilly and Novo Nordisk announce significant price reductions for popular weight-loss medications after Trump's intervention.
Danish pharmaceutical giant Novo Nordisk faces turbulent times as Q3 profits drop 27% despite Ozempic's success. The company announces massive restructuring with 9,000 job cuts worldwide. Get the inside story on what's happening behind the scenes.
Former US President Donald Trump is negotiating with Novo Nordisk to offer weight-loss drugs at just $149. Discover how this could revolutionize affordable healthcare and impact India's growing obesity crisis.
Breaking news: US FDA approves Rybelsus, the groundbreaking oral weight loss medication that mimics popular injection drugs. Discover how this pill could revolutionise obesity treatment in India and worldwide.
Former Novo Nordisk CEO Lars Fruergaard Jørgensen reveals why revolutionary weight-loss drugs need comprehensive healthcare strategies to tackle obesity effectively. Discover the missing pieces in the fight against this global epidemic.
Danish pharma giant Novo Nordisk, the company behind diabetes & weight-loss blockbusters Ozempic and Wegovy, announces a major boardroom reshuffle. Get the inside scoop on the new faces and strategic direction.